Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
Abstract Hepatocellular carcinoma (HCC) is a malignancy with high morbidity and mortality but lacks effective treatments thus far. Although the emergence of immune checkpoint inhibitors in recent years has shed light on the treatment of HCC, a considerable number of patients are still unable to achi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-023-03051-0 |
| _version_ | 1797556336543662080 |
|---|---|
| author | Rui Han Changquan Ling Yuqian Wang Lingeng Lu |
| author_facet | Rui Han Changquan Ling Yuqian Wang Lingeng Lu |
| author_sort | Rui Han |
| collection | DOAJ |
| description | Abstract Hepatocellular carcinoma (HCC) is a malignancy with high morbidity and mortality but lacks effective treatments thus far. Although the emergence of immune checkpoint inhibitors in recent years has shed light on the treatment of HCC, a considerable number of patients are still unable to achieve durable and ideal clinical benefits. Therefore, refining the combination of immune checkpoint inhibitors (ICIs) to enhance the therapeutic effect has become a global research hotspot. Several histone deacetylase 2 inhibitors have shown advantages in ICIs in many solid cancers, except for HCC. Additionally, the latest evidence has shown that histone deacetylase 2 inhibition can regulate PD-L1 acetylation, thereby blocking the nuclear translocation of PD-L1 and consequently enhancing the efficacy of PD-1/PD-L1 inhibitors and improving anti-cancer immunity. Moreover, our team has recently discovered a novel HDAC2 inhibitor (HDAC2i), valetric acid (VA), that possesses great potential in HCC treatment as a monotherapy. Thus, a new combination strategy, combining HDAC2 inhibitors with ICIs, has emerged with significant development value. This perspective aims to ignite enthusiasm for exploring the application of ideal HDAC2 inhibitors with solid anti-tumor efficacy in combination with immunotherapy for HCC. |
| first_indexed | 2024-03-10T17:00:19Z |
| format | Article |
| id | doaj.art-d7bab4febdb04aaf8fa58af66a449011 |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-03-10T17:00:19Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-d7bab4febdb04aaf8fa58af66a4490112023-11-20T10:59:47ZengBMCCancer Cell International1475-28672023-09-0123111110.1186/s12935-023-03051-0Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibitionRui Han0Changquan Ling1Yuqian Wang2Lingeng Lu3Department of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical UniversityDepartment of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical UniversityDepartment of Chinese Medicine Oncology, The First Affiliated Hospital of Naval Medical UniversitySchool of Medicine, Center for Biomedical Data Science, Yale UniversityAbstract Hepatocellular carcinoma (HCC) is a malignancy with high morbidity and mortality but lacks effective treatments thus far. Although the emergence of immune checkpoint inhibitors in recent years has shed light on the treatment of HCC, a considerable number of patients are still unable to achieve durable and ideal clinical benefits. Therefore, refining the combination of immune checkpoint inhibitors (ICIs) to enhance the therapeutic effect has become a global research hotspot. Several histone deacetylase 2 inhibitors have shown advantages in ICIs in many solid cancers, except for HCC. Additionally, the latest evidence has shown that histone deacetylase 2 inhibition can regulate PD-L1 acetylation, thereby blocking the nuclear translocation of PD-L1 and consequently enhancing the efficacy of PD-1/PD-L1 inhibitors and improving anti-cancer immunity. Moreover, our team has recently discovered a novel HDAC2 inhibitor (HDAC2i), valetric acid (VA), that possesses great potential in HCC treatment as a monotherapy. Thus, a new combination strategy, combining HDAC2 inhibitors with ICIs, has emerged with significant development value. This perspective aims to ignite enthusiasm for exploring the application of ideal HDAC2 inhibitors with solid anti-tumor efficacy in combination with immunotherapy for HCC.https://doi.org/10.1186/s12935-023-03051-0HCCHDAC inhibitorImmune therapyOncotherapy sensitizerPD-L1 nuclear translocation |
| spellingShingle | Rui Han Changquan Ling Yuqian Wang Lingeng Lu Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition Cancer Cell International HCC HDAC inhibitor Immune therapy Oncotherapy sensitizer PD-L1 nuclear translocation |
| title | Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition |
| title_full | Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition |
| title_fullStr | Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition |
| title_full_unstemmed | Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition |
| title_short | Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition |
| title_sort | enhancing hcc treatment innovatively combining hdac2 inhibitor with pd 1 pd l1 inhibition |
| topic | HCC HDAC inhibitor Immune therapy Oncotherapy sensitizer PD-L1 nuclear translocation |
| url | https://doi.org/10.1186/s12935-023-03051-0 |
| work_keys_str_mv | AT ruihan enhancinghcctreatmentinnovativelycombininghdac2inhibitorwithpd1pdl1inhibition AT changquanling enhancinghcctreatmentinnovativelycombininghdac2inhibitorwithpd1pdl1inhibition AT yuqianwang enhancinghcctreatmentinnovativelycombininghdac2inhibitorwithpd1pdl1inhibition AT lingenglu enhancinghcctreatmentinnovativelycombininghdac2inhibitorwithpd1pdl1inhibition |